TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT02693535: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Sponsor: American Society of Clinical Oncology · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 4200 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$13,998,600

Rescue Site Savings

+$9,240,000

Unlock Full NCT02693535 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02693535 Rescue Dossier →